Coegin Pharma AB Announces Successful Dual-Listing on Börse Stuttgart

Coegin Pharma AB, a Swedish biotechnology company, has announced the successful completion of the application process for the dual-listing of its shares on Börse Stuttgart. The first trading day on Börse Stuttgart is today, July 1, 2024. This milestone is part of the Nordic Growth Market NGM AB ("NGM") Reach program, which leverages the primary listing in Sweden and makes shares primarily listed on NGM available through the "Nordic Growth Market" segment on Börse Stuttgart.

The dual-listing on Börse Stuttgart, the sixth-largest exchange group in Europe with over 2 million listed securities, provides Coegin Pharma with access to a broader network of investors through a truly European listing platform. This strategic move aims to enhance the company's visibility and attract a more diverse shareholder base.

"We are pleased that our shares are now available to a broader investor base in Europe. We look forward to welcoming new shareholders and continuing our work on the pre-launch activities for our focus project on hair growth," said Jens Eriksson, CEO of Coegin Pharma. The company is actively engaged in pre-launch activities for its hair growth project, which is expected to generate significant interest among new and existing investors.

To further support its expansion into the European market, Coegin's management will participate in a listing event in Stuttgart this fall. Additionally, communication activities to reach investors at Börse Stuttgart will commence after the summer break. In conjunction with the dual-listing, Coegin will start using English in its various communication channels to better reach an international audience. The company's website is already available in both Swedish and English, reflecting its commitment to transparency and accessibility.

Coegin Pharma's strategic focus includes developing and commercializing dermocosmetic products in partnership with leading commercial players and early out-licensing "first-in-class" drug candidates to major pharmaceutical companies. The company's innovative projects have significant potential for treating serious diseases such as cancer and heart attack, as well as improving the quality of life for individuals seeking cosmetic solutions for hair growth.

For further information, please contact:
Jens Eriksson, CEO
Email: info@coeginpharma.com
Phone: +46 72 221 24 21

This document is a translation of the original Swedish press release. In case of any discrepancies, the Swedish version shall prevail.

About Coegin Pharma:
Coegin Pharma is a Swedish biotechnology company with several innovative groundbreaking drug candidates and dermocosmetic products. The company's projects have great potential for treating patients with serious diseases such as cancer and heart attack, as well as improving the quality of life for people in need of cosmetic products for hair growth. The strategy is to create value by developing and commercializing dermocosmetic products in partnership with leading commercial players and by early out-licensing "first-in-class" drug candidates to major pharmaceutical companies.

For further information: www.coeginpharma.com/en

Considering the successful dual-listing on Börse Stuttgart and the company's strategic initiatives, investors should consider holding their shares to benefit from potential future growth and increased market visibility.